Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers.

Pharmaceutical

Acumen Pharmaceuticals

Daniel O’Connell

Alex Braun

Kristen Elkins

Julie Bockenstette

Amber Dilley

Kasey Spencer

David Potter

Derek Meisner

Matthew Zuga

Russell Barton

Eric Siemers

Jerry Moore

Research and Development

Clinical Operations Team

Leadership Team

Medical and Legal Affairs

Finance and Accounting

Teams at Acumen Pharmaceuticals

Research and Development

Clinical Operations Team

Leadership Team

Medical and Legal Affairs

Finance and Accounting